Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...